Table 2 Association of clinicopathologic features with time to biochemical failure using univariate Cox regression models
From: Evaluation of protein biomarkers of prostate cancer aggressiveness
Variable | N | % | HR (95% CI) | P-value |
|---|---|---|---|---|
Total population | 160 | Â | Â | Â |
Combined Gleason score | Â | Â | Â | 0.034 |
 3 + 3 | 50 | 31.3 | 0.09 (0.02-0.51) |  |
 3 + 4 | 63 | 39.4 | 0.17 (0.03-0.78) |  |
 4 + 3 | 34 | 21.3 | 0.17 (0.03-0.92) |  |
 4 + 4 | 8 | 5.0 | 0.11 (0.01-1.23) |  |
 4 + 5 | 5 | 3.1 | 1.00 |  |
Primary Gleason pattern | Â | Â | Â | 0.347 |
 3 | 113 | 70.6 | 0.65 (0.27-1.58) |  |
 4 | 47 | 29.4 | 1.00 |  |
Pathologic stage | Â | Â | Â | 0.013 |
 Extraprostatic extension (pT3+) | 29 | 18.1 | 3.13 (1.28-7.69) |  |
 Prostate-limited (pT2) | 131 | 81.9 | 1.00 |  |
Lymph node involvement | Â | Â | Â | 0.018 |
 Yes (pN1) | 5 | 3.1 | 4.46 (1.29-15.37) |  |
 No (pN0) | 155 | 96.9 | 1.00 |  |
Surgical margin involvement | Â | Â | Â | 0.022 |
 Yes (pR1) | 53 | 33.1 | 2.82 (1.17-6.84) |  |
 No (pR0) | 107 | 66.9 | 1.00 |  |
Non-Localized tumor Indicator* | Â | Â | Â | 0.005 |
 Yes | 67 | 41.9 | 4.21 (1.54-11.50) |  |
 No | 93 | 58.1 | 1.00 |  |
| Â | N | Mean (SD) | HR (95% CI) | P-value |
Age (years) | 160 | 60.8 (6.8) | 1.08 (1.01-1.16) | 0.035 |
Pre-operative PSA (ng/mL) | 148 | 7.2 (5.3) | 1.03 (0.98-1.09) | 0.238 |